Re­gen­eron re­veals da­ta be­hind de­pri­or­i­tized BC­MA/CD3 bis­pe­cif­ic: #AACR23

OR­LAN­DO – Re­gen­eron on Mon­day re­vealed the da­ta be­hind one of its BC­MA and CD3-di­rect­ed bis­pe­cif­ic an­ti­bod­ies that it has de­cid­ed not to take for­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA